--- title: "Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Short Interest Update" type: "News" locale: "en" url: "https://longbridge.com/en/news/281064722.md" description: "Inventiva S.A. Sponsored ADR (NASDAQ:IVA) experienced an 18.7% decrease in short interest in March, totaling 447,124 shares. Currently, 0.5% of the stock is sold short, with a short-interest ratio of 1.5 days based on an average daily volume of 296,385 shares. Analysts have mixed ratings, with three Strong Buy, six Buy, and one Sell. The average price target is $16.56. Recently, IVA stock traded down 5.2% to $5.42, with a one-year range of $2.85 to $7.98. Institutional investors hold 19.06% of the stock." datetime: "2026-03-30T18:18:21.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/281064722.md) - [en](https://longbridge.com/en/news/281064722.md) - [zh-HK](https://longbridge.com/zh-HK/news/281064722.md) --- # Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Short Interest Update Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) was the target of a large decrease in short interest during the month of March. As of March 13th, there was short interest totaling 447,124 shares, a decrease of 18.7% from the February 26th total of 549,755 shares. Based on an average daily volume of 296,385 shares, the short-interest ratio is currently 1.5 days. Currently, 0.5% of the shares of the stock are short sold. ## Wall Street Analysts Forecast Growth Several equities research analysts have recently issued reports on the company. HC Wainwright set a $24.00 target price on Inventiva and gave the stock a "buy" rating in a report on Wednesday, January 28th. UBS Group assumed coverage on Inventiva in a research note on Wednesday, January 7th. They set a "buy" rating and a $12.00 price target for the company. Barclays began coverage on Inventiva in a report on Tuesday, January 27th. They set an "overweight" rating and a $18.00 price target for the company. Truist Financial started coverage on Inventiva in a research note on Thursday, March 19th. They issued a "buy" rating and a $13.00 price objective on the stock. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Inventiva in a report on Thursday, January 22nd. Three research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $16.56. **Get Our Latest Stock Analysis on Inventiva** ## Inventiva Trading Down 5.2% IVA stock traded down $0.30 during mid-day trading on Monday, reaching $5.42. 157,501 shares of the stock traded hands, compared to its average volume of 432,078. Inventiva has a one year low of $2.85 and a one year high of $7.98. The business has a 50-day moving average price of $6.30 and a two-hundred day moving average price of $5.38. ## Institutional Trading of Inventiva A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IVA. Creative Planning bought a new stake in Inventiva in the second quarter worth about $32,000. Virtu Financial LLC bought a new position in shares of Inventiva during the fourth quarter valued at approximately $60,000. XTX Topco Ltd purchased a new stake in shares of Inventiva in the fourth quarter worth approximately $84,000. NewEdge Advisors LLC purchased a new stake in shares of Inventiva in the third quarter worth approximately $116,000. Finally, Cerity Partners LLC bought a new stake in shares of Inventiva during the 4th quarter worth approximately $93,000. 19.06% of the stock is owned by hedge funds and other institutional investors. ## Inventiva Company Profile (Get Free Report) Inventiva NASDAQ: IVA is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company's core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva's scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates. The company's lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies. ## Further Reading - Five stocks we like better than Inventiva _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in Inventiva Right Now? Before you consider Inventiva, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inventiva wasn't on the list. While Inventiva currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [IVA.US](https://longbridge.com/en/quote/IVA.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) ## Related News & Research - [Assessing Inventiva (ENXTPA:IVA) Valuation After Recent Share Price Volatility](https://longbridge.com/en/news/286962960.md) - [US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug](https://longbridge.com/en/news/286394551.md) - [Lantern Pharma raises capital, plans AI platform spinoff](https://longbridge.com/en/news/286480334.md) - [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md) - [Guardant Health Says US FDA Approved Liquid Biopsy Test](https://longbridge.com/en/news/287069625.md)